Skip to main content
Skip to section navigation
Skip to footer
Home
About Us
Overview
Management Team
Board of Directors
Scientific Advisory Board
Clinical Advisory Board
Our Science
Product Pipeline
Overview
Alzheimer’s Disease
ALS
MSA
Parkinson’s Disease
Posters & Publications
News & Media
Press Releases
Events
In The News
Videos
Commentary
Podcasts
Investors
Overview
News & Events
Company Info
Financial Results
Stock Data
SEDAR
SEC Filings
Governance
Careers
Contact
SEC Filings
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Management Team
Presentations
Contacts
FAQ
Financial Results
Stock Data
NASDAQ: PMN
Analyst Coverage
SEDAR
SEC Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Filing Type:
View All
10-12B
10-12B/A
10-K
10-K/A
10-Q
3
4
424B3
424B5
8-K
ARS
CERT
CORRESP
D
D/A
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
POS AM
PRE 14A
REGDEX
S-1
S-1/A
S-3
S-3/A
S-8
SC 13G
SC 13G/A
SCHEDULE 13G/A
SEC STAFF ACTION
SEC STAFF LETTER
SUPPL
UPLOAD
Year:
View All
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
Date
Form
Description
PDF
Pages
09/09/24
DEF 14A
Definitive proxy statements
22
09/06/24
EFFECT
Notice of Effectiveness
1
09/04/24
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
09/03/24
UPLOAD
SEC-generated letter
Documents
expand_more
TEXT-EXTRACT
1
08/29/24
S-3
Registration statement for specified transactions by certain issuers
Documents
expand_more
EX-5.1
EX-23.1
EX-FILING FEES
35
08/29/24
PRE 14A
Preliminary proxy statement not related to a contested matter or merger/acquisition
22
08/16/24
4
Statement of changes in beneficial ownership of securities
1
08/08/24
10-Q
Quarterly report pursuant to Section 13 or 15(d)
Documents
expand_more
EX-31.1
EX-31.2
EX-32.1
39
08/08/24
8-K
Current report filing
Documents
expand_more
EX-99.1
8
08/05/24
SC 13G
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
9
arrow_back
1
2
3
4
5
6
7
8
9
10
…24
arrow_forward
Email Alerts
Contacts